{"database": "lobbying", "table": "lobbying_activities", "rows": [[2824625, "dd2d3682-a0e3-4555-867c-5a9633c77136", "Q2", "AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS", 3457, "AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS", 2022, "second_quarter", "PHA", "Communication with Senate to pass insulin affordability legislation. Discussion with White House requesting response to drug contrast shortages. Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Conversation with DEA regulation on Medication-Assisted Treatment and drug shortages. Discussed COVID-19 response recommendations with House and Senate Offices, White House Offices, and HHS and its sub-agencies, and DEA. Contact HHS, House and Senate Offices concerning rule enforcement of the 340B Drug Pricing Program. Met with House and Senate offices to discuss the Protect 340B Act (H.R. 4390) and bills S.773 and H.R. 3203, also related to the 340B program. Discussed role out of Test to Treat Program with HHS and its agencies.", "Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE", null, 528641, 0, 0, "2022-07-18T14:23:24-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["2824625"], "units": {}, "query_ms": 25.66279796883464, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}